Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CCR2 Antagonist
BMS-741672 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| A1 | EXPERIMENTAL | - |
| A2 | PLACEBO_COMPARATOR | - |
| A | EXPERIMENTAL | - |
| B | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| CCR2 Antagonist | DRUG | Tablets, Oral, 50 mg, once daily, 12 weeks |
| Placebo | DRUG | Tablets, Oral, 0mg, once daily, 12 weeks |
| BMS-741672 | DRUG | Tablets, Oral, 100 mg, once daily, 3 weeks |
Inclusion Criteria: * Drug-naive Type 2 diabetics with a screening HbA1c of ≥ 7.5% and ≤ 10% * Screening FPG ≥ 140 mg/dL and ≤ 220 mg/dL * BMI ≤ 40 kg/m2 Exclusion Criteria: * Active tuberculosis * Symptoms of poorly controlled diabetes * History of diabetic ketoacidosis * Significant cardiovascu...
Top 3 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE2 | LY3016859, LY3556050, LY3526318, LY3857210, LY4065967 ISA |
| Dogwood Therapeutics Inc | DWTX | 1 | PHASE2 | Halneuron |
| Sangamo Therapeutics, Inc. | SGMO | 1 | PHASE1 | ST-503 |
BMS-741672 is an investigational small molecule developed by Bristol-Myers Squibb Company (ticker BMY) for the treatment of neuropathic pain. It is a CCR2 antagonist that has been studied in a Phase 2 clinical trial. It is not an approved therapy and remains in clinical development.
BMS-741672 was studied for the treatment of neuropathic pain, specifically diabetic neuropathic pain. Its only recorded clinical trial enrolled adults with neuropathic pain in the United States. The drug is investigational and has not been approved for any indication.
BMS-741672 targets CCR2, a chemokine receptor. It acts as a CCR2 antagonist, meaning it blocks this receptor rather than activating it. This mechanism was the basis for its evaluation in neuropathic pain, a condition where CCR2 signaling has been studied.
Bristol-Myers Squibb Company, which trades under the ticker BMY, is the developer of BMS-741672. The company sponsored the Phase 2 trial of the drug in diabetic neuropathic pain conducted in the United States.
BMS-741672 is in Phase 2 development. Its single recorded trial, NCT00683423, was a completed Phase 2 study. The drug is investigational and has not received FDA approval for any indication.
BMS-741672 has been evaluated in one clinical trial, NCT00683423, titled BMS-741672 for Diabetic Neuropathic Pain. It was a completed Phase 2, randomized, double-blind, placebo-controlled study that enrolled 50 adults aged 18 years and older in the United States.